Mediators involved in retinopathy of prematurity and emerging therapeutic targets

Early Human Development

Volumn 87, Issue 10, 2011, Pages 683-690

  Mataftsi, A ^a,b   Dimitrakos, S A ^b   Adams, G G W ^a,c  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

Mediators; Molecules; Pathogenesis; Retinopathy of prematurity

Indexed keywords

ALPHA TOCOPHEROL DERIVATIVE; ANGIOGENIC FACTOR; BEVACIZUMAB; FRESH FROZEN PLASMA; GRANULOCYTE COLONY STIMULATING FACTOR; KETOROLAC TROMETAMOL; MELATONIN; OXYGEN; PEROXYNITRITE; RANIBIZUMAB; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT SOMATOMEDIN B; RECOMBINANT SOMATOMEDIN C; RESVERATROL; SOMATOMEDIN C; TRANSCRIPTION FACTOR NRF2; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN INHIBITOR; VISUAL PIGMENT;

ANEMIA; DRUG MEGADOSE; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; IRON THERAPY; LASER COAGULATION; LOW DRUG DOSE; LOW LEVEL LASER THERAPY; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; RETROLENTAL FIBROPLASIA; REVIEW; SIGNAL TRANSDUCTION; TREATMENT PLANNING; TREATMENT RESPONSE;

ERYTHROPOIETIN; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INFANT, NEWBORN; INSULIN-LIKE GROWTH FACTOR I; OXIDATIVE STRESS; PROTEIN ISOFORMS; RETINOPATHY OF PREMATURITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80053051500     PISSN: 03783782     EISSN: 18726232     Source Type: Journal    
DOI: 10.1016/j.earlhumdev.2011.05.009     Document Type: Review

References (103)

1. Gilbert C., Fielder A., Gordillo L., Quinn G., Semiglia R., Visintin P., et al. Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs. Pediatrics 2005, 115:e518-e525.
2. Chen J., Smith L.E. Retinopathy of prematurity. Angiogenesis 2007, 10(2):133-140.
3. Fleck B., Mclntosh N. Pathogenesis of retinopathy of prematurity and possible preventive strategies. Early Hum Dev 2008, 84:83-88.
4. Zhang F., Tang Z., Hou X., Lennartsson J., Li Y., Koch A.W., et al. VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc Natl Acad Sci USA 2009 Apr 14, 106(15):6152-6157.
5. Woolard J., Wang W.Y., Bevan H.S., Qiu Y., Morbidelli L., Pritchard-Jones R.O., et al. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res 2004, 64(21):7822-7835.
6. Magnussen A.L., Rennel E.S., Hua J., Bevan H.S., Beazley Long N., Lehrling C., et al. VEGF-A165b is cytoprotective and anti-angiogenic in the retina. Invest Ophthalmol Vis Sci 2010, 51(8):4273-4281.
7. Nakamura M., Abe Y., Tokunaga T. Pathological significance of vascular endothelial growth factor A isoform expression in human cancer. Pathol Int 2002, 52(5-6):331-339.
8. Yuan A, Lin CY, Chou CH, Shih CM, Chen CY, Cheng HW et al. Functional and structural characteristics of tumor angiogenesis in lung cancers overexpressing different VEGF isoforms assessed by DCE- and SSCE-MRI. PLoS One. 2011 Jan 20;6(1):e16062.
9. Lohela M., Bry M., Tammela T., Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 2009, 21(2):154-165.
10. Qazi Y., Maddula S., Ambati B.K. Mediators of ocular angiogenesis. J Genet 2009, 88(4):495-515.
11. Harper SJ, Bates DO. VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer. 2008 Nov;8(11):880-7.
12. Penn J.S., Madan A., Caldwell R.B., Bartoli M., Caldwell R.W., Hartnett M.E. Vascular endothelial growth factor in eye disease. Prog Retin Eye Res 2008, 27(4):331-371.
13. Nowak D.G., Woolard J., Amin E.M., Konopatskaya O., Saleem M.A., Churchill A.J., et al. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. J Cell Sci 2008, 121(Pt 20):3487-3495.
14. Gunther J.B., Altaweel M.M. Bevacizumab (Avastin) for the treatment of ocular disease. Surv Ophthalmol 2009, 54(3):372-400.
15. Ciulla T.A., Rosenfeld P.J. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. Curr Opin Ophthalmol 2009, 20(3):158-165.
16. Travassos A., Teixeira S., Ferreira P., Regadas I., Travassos A.S., Esperancinha F.E., et al. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Lasers Imaging 2007, 3:233-237.
17. Shah P.K., Narendran V., Tawansy K.A., Raghuram A., Narendran K. Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol 2007, 55(1):75-76.
18. Chung E.J., Kim J.H., Ahn H.S., Koh H.J. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2007, 245(11):1727-1730.
19. Honda S., Hirabayashi H., Tsukahara Y., Negi A. Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2008, 246(7):1061-1063.
20. Kusaka S., Shima C., Wada K., Arahori H., Shimojyo H., Sato T., et al. Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. Br J Ophthalmol 2008, 92(11):1450-1455.
21. Mintz-Hittner H.A., Kuffel R.R. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina 2008, 28(6):831-838.
22. Quiroz-Mercado H., Martinez-Castellanos M.A., Hernandez-Rojas M.L., Salazar-Teran N., Chan R.V. Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina 2008, 28(Suppl. 3):S19-S25.
23. Lalwani G.A., Berrocal A.M., Murray T.G., Buch M., Cardone S., Hess D., et al. Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina 2008, 28(Suppl. 3):S13-S18.
24. Law J.C., Recchia F.M., Morrison D.G., Donahue S.P., Estes R.L. Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity. J AAPOS 2010, 14(1):6-10.
25. Löfqvist C., Niklasson A., Engström E., Friberg L.E., Camacho-Hübner C., Ley D., et al. A pharmacokinetic and dosing study of intravenous insulin-like growth factor-I and IGF-binding protein-3 complex to preterm infants. Pediatr Res 2009, 65(5):574-579.
26. Hansen-Pupp I., Engström E., Niklasson A., Berg A.C., Fellman V., Löfqvist C., et al. Fresh-frozen plasma as a source of exogenous insulin-like growth factor-I in the extremely preterm infant. J Clin Endocrinol Metab 2009, 94(2):477-482.
27. Aher S.M., Ohlsson A. Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2006, 3:CD004865.
28. Suk K.K., Dunbar J.A., Liu A., Daher N.S., Leng C.K., Leng J.K., et al. Human recombinant erythropoietin and the incidence of retinopathy of prematurity: a multiple regression model. J AAPOS 2008, 12(3):233-238.
29. Fortes Filho J.B., Eckert G.U., Valiatti F.B., Dos Santos P.G., da Costa M.C., Procianoy R.S. The influence of gestational age on the dynamic behavior of other risk factors associated with retinopathy of prematurity (ROP). Graefes Arch Clin Exp Ophthalmol 2010, 248(6):893-900.
30. Schneider J.K., Gardner D.K., Cordero L. Use of recombinant human erythropoietin and risk of severe retinopathy in extremely low-birth-weight infants. Pharmacotherapy 2008, 28(11):1335-1340.
31. Shah N., Jadav P., Jean-Baptiste D., Weedon J., Cohen L.M., Kim M.R. The effect of recombinant human erythropoietin on the development of retinopathy of prematurity. Am J Perinatol 2010, 27(1):67-71.
32. Bhola R., Purkiss T., Hunter S., Stewart D., Rychwalski P.J. Effect of granulocyte colony-stimulating factor on the incidence of threshold retinopathy of prematurity. J AAPOS 2009, 13(5):450-453.
33. Raju T.N., Langenberg P., Bhutani V., Quinn G.E. Vitamin E prophylaxis to reduce retinopathy of prematurity: a reappraisal of published trials. J Pediatr 1997, 131(6):844-850.
34. Lee J.Y., Chae J.B., Yang S.J., Yoon Y.H., Kim J.G. Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels. Graefes Arch Clin Exp Ophthalmol 2010, 248(9):1257-1262.
35. Dorta P., Kychenthal A. Treatment of type 1 retinopathy of prematurity with intravitreal bevacizumab (Avastin). Retina 2010, 30(Suppl. 4):S24-S31.
36. Mintz-Hittner H.A., Kennedy K.A. BEAT-ROP cooperative group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011, 364(7):603-615.
37. Kawamura H., Li X., Harper S.J., Bates D.O., Claesson-Welsh L. Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity. Cancer Res 2008, 15;68(12):4683-4692.
38. Hua J., Spee C., Kase S., Rennel E.S., Magnussen A.L., Qiu Y., et al. Recombinant human VEGF165b inhibits experimental choroidal neovascularisation. Invest Ophthalmol Vis Sci 2010, 51(8):4282-4288.
39. Guo S., Colbert L.S., Fuller M., Zhang Y., Gonzalez-Perez R.R. Vascular endothelial growth factor receptor-2 in breast cancer. Biochim Biophys Acta 2010, 1806(1):108-121.
40. Xia X.B., Xiong S.Q., Song W.T., Luo J., Wang Y.K., Zhou R.R. Inhibition of retinal neovascularization by siRNA targeting VEGF(165). Mol Vis 2008, 14:1965-1973.
41. Dausse E., Da Rocha Gomes S., Toulmé J.J. Aptamers: a new class of oligonucleotides in the drug discovery pipeline?. Curr Opin Pharmacol 2009, 9(5):602-607.
42. Kase S., He S., Sonoda S., Kitamura M., Spee C., Wawrousek E., et al. AlphaB-crystallin regulation of angiogenesis by modulation of VEGF. Blood 2010, 115(16):3398-3406.
43. Gautier B., Goncalves V., Diana D., Di Stasi R., Teillet F., Lenoir C., et al. Biochemical and structural analysis of the binding determinants of a vascular endothelial growth factor receptor peptidic antagonist. J Med Chem 2010, 53(11):4428-4440.
44. Giordano R.J., Cardó-Vila M., Salameh A., Anobom C.D., Zeitlin B.D., Hawke D.H., et al. From combinatorial peptide selection to drug prototype (I): targeting the vascular endothelial growth factor receptor pathway. Proc Natl Acad Sci USA 2010, 107(11):5112-5117.
45. Hu J., Qu C., Yu Y., Ping M., Wei D., Dandan D. Protamine sulfate downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF and its receptor binding in vitro. Adv Exp Med Biol 2010, 664:341-347.
46. Nakamura S., Chikaraishi Y., Tsuruma K., Shimazawa M., Hara H. Ruboxistaurin, a PKCbeta inhibitor, inhibits retinal neovascularization via suppression of phosphorylation of ERK1/2 and Akt. Exp Eye Res 2010, 90(1):137-145.
47. Guma M., Rius J., Duong-Polk K.X., Haddad G.G., Lindsey J.D., Karin M. Genetic and pharmacological inhibition of JNK ameliorates hypoxia-induced retinopathy through interference with VEGF expression. Proc Natl Acad Sci USA 2009, 106(21):8760-8765.
48. Zhang Q., Wang D., Kundumani-Sridharan V., Gadiparthi L., Johnson D.A., Tigyi G.J., et al. PLD1-dependent PKC{gamma} activation downstream to Src is essential for the development of pathological retinal neovascularization. Blood 2010, 116(8):1377-1385.
49. Sato T., Kusaka S., Shimojo H., Fujikado T. Simultaneous analyses of vitreous levels of 27 cytokines in eyes with retinopathy of prematurity. Ophthalmology 2009, 116(11):2165-2169.
50. Hellstrom A., Perruzzi C., Ju M., Engstrom E., Hard A.L., Liu J.L., et al. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci USA 2001, 98(10):5804-5808.
51. Löfqvist C., Andersson E., Sigurdsson J., Engström E., Hård A.L., Niklasson A., et al. Longitudinal postnatal weight and insulin-like growth factor I measurements in the prediction of retinopathy of prematurity. Arch Ophthalmol 2006, 124(12):1711-1718.
52. Ma Q.L., Yang T.L., Yin J.Y., Peng Z.Y., Yu M., Liu Z.Q., et al. Role of insulin-like growth factor-1 (IGF-1) in regulating cell cycle progression. Biochem Biophys Res Commun 2009, 389(1):150-155.
53. Jogie-Brahim S., Feldman D., Oh Y. Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocr Rev 2009, 30(5):417-437.
54. Kielczewski J.L., Jarajapu Y.P., McFarland E.L., Cai J., Afzal A., Li Calzi S., et al. Insulin-like growth factor binding protein-3 mediates vascular repair by enhancing nitric oxide generation. Circ Res 2009, 105(9):897-905.
55. Löfqvist C., Chen J., Connor K.M., Smith A.C., Aderman C.M., Liu N., et al. IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth. Proc Natl Acad Sci USA 2007, 104(25):10589-10594.
56. Watanabe D., Suzuma K., Matsui S., Kurimoto M., Kiryu J., Kita M., et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 2005, 353(8):782-792.
57. Chen J., Connor K.M., Aderman C.M., Smith L.E. Erythropoietin deficiency decreases vascular stability in mice. J Clin Invest 2008, 118(2):526-533.
58. Haribalaganesh R., Sheikpranbabu S., Banumathi E., Gurunathan S. Pigment epithelium-derived factor inhibits erythropoietin-induced retinal endothelial cell angiogenesis by suppression of PI3K/Akt pathway. Exp Eye Res 2010, 90(6):726-733.
59. Sato T., Kusaka S., Shimojo H., Fujikado T. Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity. Ophthalmology 2009, 116(9):1599-1603.
60. Chen J., Connor K.M., Aderman C.M., Willett K.L., Aspegren O.P., Smith L.E. Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy. Invest Ophthalmol Vis Sci 2009, 50(3):1329-1335.
61. Xiong S.Q., Xia X.B., Xu H.Z., Jiang J. Suppression of retinal neovascularization by small-interference RNA targeting erythropoietin. Ophthalmologica 2009, 223(5):306-312.
62. Demetri G.D., Griffin J.D. Granulocyte colony-stimulating factor and its receptor. Blood 1991, 78(11):2791-2808.
63. Tura O., Crawford J., Barclay G.R., Samuel K., Hadoke P.W., Roddie H., et al. Granulocyte colony-stimulating factor (G-CSF) depresses angiogenesis in vivo and in vitro: implications for sourcing cells for vascular regeneration therapy. J Thromb Haemost 2010, 8(7):1614-1623.
64. Andrae J., Gallini R., Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008, 22(10):1276-1312.
65. Hou X., Kumar A., Lee C., Wang B., Arjunan P., Dong L., et al. PDGF-CC blockade inhibits pathological angiogenesis by acting on multiple cellular and molecular targets. Proc Natl Acad Sci USA 2010, 107(27):12216-12221.
66. Kumar A., Hou X., Lee C., Li Y., Maminishkis A., Tang Z., et al. Platelet-derived growth factor-DD targeting arrests pathological angiogenesis by modulating glycogen synthase kinase-3beta phosphorylation. J Biol Chem 2010, 285(20):15500-15510.
67. Tombran-Tink J. PEDF in angiogenic eye diseases. Curr Mol Med 2010, 10(3):267-278.
68. Amaral J., Becerra S.P. Effects of human recombinant PEDF protein and PEDF-derived peptide 34-mer on choroidal neovascularization. Invest Ophthalmol Vis Sci 2010, 51(3):1318-1326.
69. Lima e Silva R., Shen J., Hackett S.F., Kachi S., Akiyama H., Kiuchi K., et al. The SDF-1/CXCR4 ligand/receptor pair is an important contributor to several types of ocular neovascularization. FASEB J 2007, 21(12):3219-3230.
70. Dorrell M.I., Aguilar E., Jacobson R., Trauger S.A., Friedlander J., Siuzdak G., et al. Maintaining retinal astrocytes normalizes revascularization and prevents vascular pathology associated with oxygen-induced retinopathy. Glia 2010, 58(1):43-54.
71. Lebrin F., Deckers M., Bertolino P., Ten Dijke P. TGF-beta receptor function in the endothelium. Cardiovasc Res 2005, 65(3):599-608.
72. Ten Dijke P., Arthur H.M. Extracellular control of TGFbeta signalling in vascular development and disease. Nat Rev Mol Cell Biol 2007, 857-869.
73. Lima e Silva R., Shen J., Gong Y.Y., Seidel C.P., Hackett S.F., Kesavan K., et al. Agents that bind annexin A2 suppress ocular neovascularization. J Cell Physiol 2010, 225(3):855-864.
74. Dal Monte M., Ristori C., Videau C., Loudes C., Martini D., Casini G., et al. Expression, localization, and functional coupling of the somatostatin receptor subtype 2 in a mouse model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 2010, 51(4):1848-1856.
75. Chrzanowska-Wodnicka M., Kraus A.E., Gale D., White G.C., Vansluys J. Defective angiogenesis, endothelial migration, proliferation, and MAPK signaling in Rap1b-deficient mice. Blood 2008, 111(5):2647-2656.
76. Maier A.K., Kociok N., Zahn G., Vossmeyer D., Stragies R., Muether P.S., et al. Modulation of hypoxia-induced neovascularization by JSM6427, an integrin alpha5beta1 inhibiting molecule. Curr Eye Res 2007, 32(9):801-812.
77. Cano Mdel V., Karagiannis E.D., Soliman M., Bakir B., Zhuang W., Popel A.S., et al. A peptide derived from type 1 thrombospondin repeat-containing protein WISP-1 inhibits corneal and choroidal neovascularization. Invest Ophthalmol Vis Sci 2009, 50(8):3840-3845.
78. Chen H., Zhang M., Tang S., London N.R., Li D.Y., Zhang K. Slit-robo signaling in ocular angiogenesis. Adv Exp Med Biol 2010, 664:457-463.
79. Evans I.M., Britton G., Zachary I.C. Vascular endothelial growth factor induces heat shock protein (HSP) 27 serine 82 phosphorylation and endothelial tubulogenesis via protein kinase D and independent of p38 kinase. Cell Signal 2008, 20(7):1375-1384.
80. Sapieha P., Sirinyan M., Hamel D., Zaniolo K., Joyal J.S., Cho J.H., et al. The succinate receptor GPR91 in neurons has a major role in retinal angiogenesis. Nat Med 2008, 14(10):1067-1076.
81. Hartnett M.E. The effects of oxygen stresses on the development of features of severe retinopathy of prematurity: knowledge from the 50/10 OIR model. Doc Ophthalmol 2010, 120(1):25-39.
82. Saito Y., Uppal A., Byfield G., Budd S., Hartnett M.E. Activated NAD(P)H oxidase from supplemental oxygen induces neovascularization independent of VEGF in retinopathy of prematurity model. Invest Ophthalmol Vis Sci 2008, 49(4):1591-1598.
83. Saito Y., Geisen P., Uppal A., Hartnett M.E. Inhibition of NAD(P)H oxidase reduces apoptosis and avascular retina in an animal model of retinopathy of prematurity. Mol Vis 2007, 13:840-853.
84. Uno K., Prow T.W., Bhutto I.A., Yerrapureddy A., McLeod D.S., Yamamoto M., et al. Role of Nrf2 in retinal vascular development and the vaso-obliterative phase of oxygen-induced retinopathy. Exp Eye Res 2010, 90(4):493-500.
85. Groeger G., Mackey A.M., Pettigrew C.A., Bhatt L., Cotter T.G. Stress-induced activation of Nox contributes to cell survival signalling via production of hydrogen peroxide. J Neurochem 2009, 109(5):1544-1554.
86. Bhatt L., Groeger G., McDermott K., Cotter T.G. Rod and cone photoreceptor cells produce ROS in response to stress in a live retinal explant system. Mol Vis 2010, 16:283-293.
87. Bedard K., Krause K.H. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007, 87(1):245-313.
88. El-Benna J., Dang P.M., Périanin A. Peptide-based inhibitors of the phagocyte NADPH oxidase. Biochem Pharmacol 2010, 80(6):778-785.
89. Kaur C., Sivakumar V., Foulds W.S., Luu C.D., Ling E.A. Cellular and vascular changes in the retina of neonatal rats after an acute exposure to hypoxia. Invest Ophthalmol Vis Sci 2009, 50(11):5364-5374.
90. Kermorvant-Duchemin E., Sapieha P., Sirinyan M., Beauchamp M., Checchin D., Hardy P., et al. Understanding ischemic retinopathies: emerging concepts from oxygen-induced retinopathy. Doc Ophthalmol 2010, 120(1):51-60.
91. Komeima K., Rogers B.S., Campochiaro P.A. Antioxidants slow photoreceptor cell death in mouse models of retinitis pigmentosa. J Cell Physiol 2007, 213(3):809-815.
92. Li S.Y., Fu Z.J., Ma H., Jang W.C., So K.F., Wong D., et al. Effect of lutein on retinal neurons and oxidative stress in a model of acute retinal ischemia/reperfusion. Invest Ophthalmol Vis Sci 2009, 50(2):836-843.
93. Kim W.T., Suh E.S. Retinal protective effects of resveratrol via modulation of nitric oxide synthase on oxygen-induced retinopathy. Korean J Ophthalmol 2010, 24(2):108-118.
94. DeNiro M., Al-Halafi A., Al-Mohanna F.H., Alsmadi O., Al-Mohanna F.A. Pleiotropic effects of YC-1 selectively inhibit pathological retinal neovascularization and promote physiological revascularization in a mouse model of oxygen-induced retinopathy. Mol Pharmacol 2010, 77(3):348-367.
95. Abdelsaid M.A., Pillai B.A., Matragoon S., Prakash R., Al-Shabrawey M., El-Remessy A.B. Early intervention of tyrosine nitration prevents vaso-obliteration and neovascularization in ischemic retinopathy. J Pharmacol Exp Ther 2010, 332(1):125-134.
96. Kermorvant-Duchemin E., Sennlaub F., Sirinyan M., Brault S., Andelfinger G., Kooli A., et al. Trans-arachidonic acids generated during nitrative stress induce a thrombospondin-1-dependent microvascular degeneration. Nat Med 2005, 11(12):1339-1345.
97. He T., Xing Y.Q., Zhao X.H., Ai M. Interaction between iNOS and COX-2 in hypoxia-induced retinal neovascularization in mice. Arch Med Res 2007, 38(8):807-815.
98. Connor K.M., SanGiovanni J.P., Lofqvist C., Aderman C.M., Chen J., Higuchi A., et al. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med 2007, 13(7):868-873.
99. Kociok N., Radetzky S., Krohne T.U., Gavranic C., Joussen A.M. Pathological but not physiological retinal neovascularization is altered in TNF-Rp55-receptor-deficient mice. Invest Ophthalmol Vis Sci 2006, 47(11):5057-5065.
100. Hirano Y., Sakurai E., Matsubara A., Ogura Y. Suppression of ICAM-1 in retinal and choroidal endothelial cells by plasmid small-interfering RNAs in vivo. Invest Ophthalmol Vis Sci 2010, 51(1):508-515.
101. Dimaio T.A., Wang S., Huang Q., Scheef E.A., Sorenson C.M., Sheibani N. Attenuation of retinal vascular development and neovascularization in PECAM-1-deficient mice. Dev Biol 2008, 315(1):72-88.
102. Sato T., Kusaka S., Hashida N., Saishin Y., Fujikado T., Tano Y. Comprehensive gene-expression profile in murine oxygen-induced retinopathy. Br J Ophthalmol 2009, 93(1):96-103.
103. Sood B.G., Madan A., Saha S., Schendel D., Thorsen P., Skogstrand K., et al. NICHD neonatal research network. Perinatal systemic inflammatory response syndrome and retinopathy of prematurity. Pediatr Res 2010, 67(4):394-400.